Inventiva SA

IVA

Company Profile

  • Business description

    Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

  • Contact

    50 rue de Dijon
    Daix21121
    FRA

    T: +33 380447500

    E: [email protected]

    https://www.inventivapharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    118

Stocks News & Analysis

stocks

Nvidia: Collaboration with Intel might bring some goodwill with the US

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks

What now for Santos after takeover offer collapses?

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks

Small caps are catching fire

For good reason.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,103.9022.200.24%
CAC 407,854.6167.630.87%
DAX 4023,674.53315.351.35%
Dow JONES (US)46,142.42124.100.27%
FTSE 1009,228.1119.740.21%
HKSE26,521.4023.45-0.09%
NASDAQ22,470.72209.400.94%
Nikkei 22545,623.05319.620.71%
NZX 50 Index13,263.08143.051.09%
S&P 5006,631.9631.610.48%
S&P/ASX 2008,815.6023.400.27%
SSE Composite Index3,827.024.64-0.12%

Market Movers